Write in a clean editor, then format for Psoriasis Forum in one click — DocuGuru applies the official SAGE template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Psoriasis Forum is a peer-reviewed journal published by SAGE, covering Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Rheumatoid Arthritis Research and Therapies.
| Publisher | SAGE |
|---|---|
| Reference style | Author–year (Harvard) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Psoriasis Forum, 12(3), pp. 45–58.
Formats any DOI in Psoriasis Forum style. No sign-up. |
| Publishes research in | Psoriasis: Treatment and Pathogenesis Dermatology and Skin Diseases Rheumatoid Arthritis Research and Therapies Autoimmune and Inflammatory Disorders Research Health Systems, Economic Evaluations, Quality of Life |
| ISSN | 1089-3504 |
| h-index | 11 |
| i10-index | 12 |
| Total citations | 493 |
| Top institutions publishing here | Icahn School of Medicine at Mount Sinai |
| Journal website | www.psoriasis.org |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Psoriatic arthritis is a major comorbidity of psoriasis that significantly impairs quality of life and physical function. Because skin lesions classically precede joint symptoms, dermatologists are in a unique position to identify patients at risk for psoriatic arthritis before irreversible joint damage occurs. Here we review the literature to identify the clinical and genetic factors…
The biologic agents vary considerably in terms of their long-term duration of effect. Using the definitions provided by the National Psoriasis Foundation Medical Board, the objective of this review was to compare all biologic agents with respect to time to relapse and potential for rebound. Overall, alefacept had the longest off-treatment benefit (29.9 weeks in…
Background To assess the consistency of infliximab (Remicade) response among different subgroups of patients with moderate to severe psoriasis, the impact of gender, obesity, age, baseline psoriasis severity, concomitant psoriatic arthritis (PsA), or prior therapies on response to infliximab was studied in an integrated efficacy analysis. Methods Data from three randomized, placebo-controlled clinical trials (SPIRIT,…
Background Tumor necrosis factor-alpha (TNF-α) is pivotal in the pathogenesis of psoriasis, an immune-mediated disease. Adalimumab is a fully human, IgG 1 monoclonal antibody that inhibits TNF-α. Objectives The aims of this study were to assess the efficacy and safety of adalimumab therapy for patients with moderate to severe plaque psoriasis and evaluate the duration…
The relationship between the eye and psoriasis has been recognized for decades, but the precise eye manifestations in patients with psoriasis and psoriatic arthritis are only recently coming to light. Psoriatic eye findings may include conjunctivitis, dry eye, episcleritis, and uveitis, all of which may precede articular changes. Uveitis, seen in 7% to 25% of…
